Submissions

Login or Register to make a submission.

Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.
  • The corresponding author, on behalf of all co-authors certifies that:
    a) All listed authors meet authorship criteria, have approved the manuscript and are in agreement to its submission.
    b) This submission is original: it has not been previously published, nor has it been submitted to another journal for consideration in a similar form, in any language or country, except as an abstract or preliminary report; if any part of it is not owned by the authors, appropriate permission for its reproduction has been obtained and is attached to this submission.
    c) Financial support and conflict of interest statements for all authors have been appropriately acknowledged in the the manuscript file.


    Please note:
    Manuscripts reporting the results of experimental investigation on human subjects must include full details of acceptance by the appropriate institutional committee or review board and a statement that the study was performed according to the Declaration of Helsinki has been included.
    Manuscripts reporting on a clinical trialmust include the trial's unique Registration number.


    Article submitted to Drug Target Insights - when accepted after peer review - are subject to publication fees follows:
    • Review, Original research articles and Clinical trial protocols: Euro 1500 (+ VAT as applicable)
    • Points of view, Video articles, Images explained, Short communications and Case reports: Euro 750 (+ VAT as applicable)
    Please refer to the full information online.


    This submission platform is integrated with ORCID. All authors will be invited to connect their ORCID profile to this article. Find out more about ORCID and its integration here.


    Please suggest three suitable reviewers for your manuscript entering their contact details in the Comment to Editor box below. Suggested reviewers should represent a varied panel and not be from the same country. You may also indicate opposing reviewers. All details will be treated confidentially.

Author Guidelines

Manuscripts submitted to Drug Target Insights must be an original contribution not previously published in any language or country (except as an abstract or preliminary report) and must not be under consideration for publication elsewhere.  If the manuscript submitted includes parts (quotations, tables, or illustrations) to which the authors do not own copyright, then written permission from the copyright owner must be submitted before the peer review process is completed, along with full details on the original source. Allow ample time to request and receive permission. Any permission fees required by the copyright owner are the responsibility of the authors.

Detailed submission guidelines are available here.

Submitting high quality figures enhance the reader’s experience and your research. Our Artwork Guidelines will assist you in providing artwork in the most suitable format, as we require high resolution files for all images in your submission.

Review

Reviews are intended to focus on the current state of knowledge or practice, integrating recent advances with accepted principles and practice, or summarizing and analyzing consensus view of controversial issues in knowledge of practice. A non-structured abstract is required.

Words: max 5000 (excluding figures and tables) | Figures/Tables: max 8 | References: no limit  

Original Research Article

Previously unpublished manuscripts, describing clinical, pre-clinical, epidemiological investigations, clinical trials, clinical observations, and other relevant investigations that are based on sound patient series, validated analytical methods, and appropriate statistical evaluation. Systematic reviews and meta-analysis can also be submitted as an original research article.  Original research articles should be structured as follows: Introduction (clearly stating an objective or hypothesis), Methods (describing the study design and methods applied, including the study setting and dates, patients or participants with inclusion and exclusion criteria, and/or participation or response rates, or data sources, and how these were selected for the study), Results (describing the results of the study in context with the published literature and addressing study limitations), and Conclusions (addressing relevant implications for clinical practice or health policy). A structured abstract (250 words) is required.

Words: max 3000 (excluding figures and tables) | Figures/Tables: max 6 | References: max 50 

Point of View

Points of view are intended to present viewpoints on the interpretation of recent investigations in any research area. Points of view are fully referenced, peer reviewed articles and must offer a clear presentation of the authors’ perspective and a constructive discussion.  A non-structured abstract is required.

Words: max 3000 (excluding figures/tables) | Figures/Tables: 4 | References: max 30

Video article

A video article provides author(s) with an opportunity to supply their work using visual media.

See full specifications online

Image explained

Images capture the sense of visual observation physicians experience in their daily practice and are a great tool to convey visible contents. Images should provide advances and/or unusual contributions.

See full specifications online.

Short communication

A concise report of data from original research, focused on initial findings that will be of interest to scientists in other fields.

Words: max 1500 (excluding figures and tables) | Figures/Tables: max 3 | References: max 7

Case report

Case reports will be considered if they describe a previously undescribed clinical case and are of very high importance for dissemination. Case reports must be structured as follows: Introduction (explaining the importance of the case), Case description (describing the case) and Conclusions (describing the detailed outcome of the report). A structured abstract is required (max 250 words).

Words: max 1500 (excluding figures and tables) | Figures/Tables: max 3 | References: max 7

Correspondence

Letters to the Editor and letters in reply are intended to present opinions or omments on articles published in the Journal. Letters are subject to abridgement and editing for style and content. A letter in reply must cite the title of the letter, e.g., “Response to (Title of Letter)”. An abstract is not required.

Words: max 500 (excluding figures/tables) | Figures/Tables: 1 | References: max 5

Congress report

A congress report covers scientific, medical, health policy or other healthcare related topics presented at an important scientific meeting that will be of interest to readers.

Copyright Notice

Authors contributing to Drug Target Insights agree to publish their articles under the Creative Common Attribution Non Commercial 4.0 (CC-BY-NC 4.0) license, which allows third parties to re-use the work without permission as long as the work is properly referenced and the use is non-commercial.

Privacy Statement

Personal information entered in this journal site will be used exclusively for the purposes of Drug Target Insights (DTI) and will not be made available for any other purpose or to any other party. The data collected from registered and non-registered users of this journal falls within the scope of the standard functioning of peer-reviewed journals and are detailed in the Privacy Policy. It includes information that makes communication possible for the editorial process; it is used to inform readers about the authorship and editing of content; it enables collecting aggregated data on readership behaviors, as well as tracking geopolitical and social elements of scholarly communication, in compliance with the European Union’s General Data Protection Regulation (GDPR)

For any questions, concern or comment you may have about this journal’s privacy policy or any requests concerning your personal data, please contact us.